Neurocrine Biosciences
Work Here?
About
Company Stage
IPO
Employees
1,001-5,000
Industries
Healthcare
Total Funding
N/A
Headquarters
San Diego, California
Founded
1992
Simplify's Take
What believers are saying
- FDA approval of CRENESSITY supports Neurocrine's innovative drug development strategy.
- Partnership with PANTHERx Rare enhances patient access and support for CRENESSITY.
- Neurocrine's focus on rare diseases aligns with industry trends towards first-in-class therapies.
What critics are saying
- Increased competition in CAH treatments could impact Neurocrine's market share.
- Reliance on PANTHERx Rare for distribution poses operational disruption risks.
- Potential side effects of CRENESSITY could lead to regulatory scrutiny or reduced adoption.
What makes Neurocrine Biosciences unique
- CRENESSITY is the first non-steroidal treatment for classic congenital adrenal hyperplasia.
- Neurocrine's CRENESSITY offers a novel approach with selective CRF1 receptor antagonism.
- CRENESSITY is the first new CAH treatment in 70 years, marking a significant advancement.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights
Headcount
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Neurocrine Biosciences is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today
💡
We update Neurocrine Biosciences's jobs every 8 hours, so check again soon! Browse all jobs →